Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Department of Pathogen Biology and Immunology, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Front Cell Infect Microbiol. 2019 Sep 10;9:322. doi: 10.3389/fcimb.2019.00322. eCollection 2019.
Malaria, a mosquito-borne infectious disease, is a severe health problem worldwide. As reported, some anti-malarial drugs with anti-parasitic properties also block mast cells (MCs) activities. It is hypothesized that MCs activity may be correlated with the pathogenesis of malaria. Thus, the role of MCs on malarial pathogenesis and the involved physiological action and pathways need to be further investigated. This study aimed to investigate the effect of MCs activation on malaria disease severity using KunMing mice with ANKA (ANKA) infection treated with MCs degranulator (compound 48/80, C48/80) or MCs stabilizer (disodium cromoglycate, DSCG). ANKA infection caused a dramatic increase in MCs density and level of MCs degranulation in cervical lymph node (CLN) and skin. Compared with infected control, C48/80 treatment had shortened survival time, increased parasitemia, exacerbated liver inflammation and CLN hyperplasia, accompanied with increase in vascular leakage and leukocyte number. The infected mice with C48/80 treatment also elevated the release of CCL2, CXCL1, and MMP-9 from MCs in CLN and skin, and TNF-α, IFN-γ, CCR2, and CXCR2 mRNA expression in CLN and liver. In contrast, the infected mice treated with DSCG showed longer survival time, lower parasitemia, improved liver inflammation and CLN hyperplasia, followed by a decline of vascular leakage and leukocyte number. Decreased MCs-derived CCL2, CXCL1, and MMP-9 from CLN and skin, mRNA expression in CLN and liver (TNF-α, IFN-γ, CCR2, and CXCR2) were also observed in infected mice with DSCG treatment. Our data indicated that MCs activation may facilitate the pathogenesis of ANKA infection.
疟疾是一种由蚊子传播的传染病,是全球严重的健康问题。据报道,一些具有抗寄生虫特性的抗疟药物也能阻断肥大细胞(MCs)的活性。因此,MCs 的活性可能与疟疾的发病机制有关。因此,需要进一步研究 MCs 在疟疾发病机制中的作用及其涉及的生理作用和途径。本研究旨在使用 ANKA(ANKA)感染的昆明小鼠,通过用 MCs 脱颗粒剂(复合物 48/80,C48/80)或 MCs 稳定剂(二钠色甘酸钠,DSCG)处理,来研究 MCs 激活对疟疾疾病严重程度的影响。ANKA 感染导致颈部淋巴结(CLN)和皮肤中 MCs 密度和脱颗粒水平显著增加。与感染对照组相比,C48/80 治疗组的存活时间缩短,寄生虫血症增加,肝脏炎症和 CLN 增生加剧,伴随着血管渗漏和白细胞数量增加。用 C48/80 处理的感染小鼠也增加了 CLN 和皮肤中 MCs 释放的 CCL2、CXCL1 和 MMP-9,以及 CLN 和肝脏中 TNF-α、IFN-γ、CCR2 和 CXCR2 mRNA 的表达。相反,用 DSCG 治疗的感染小鼠表现出更长的存活时间、更低的寄生虫血症、改善的肝脏炎症和 CLN 增生,随后血管渗漏和白细胞数量下降。也观察到用 DSCG 处理的感染小鼠中 CLN 和皮肤中 MCs 衍生的 CCL2、CXCL1 和 MMP-9 减少,CLN 和肝脏中 TNF-α、IFN-γ、CCR2 和 CXCR2 mRNA 的表达减少。我们的数据表明,MCs 的激活可能促进了 ANKA 感染的发病机制。